Related Experiment Video
Updated: Sep 27, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
Systemic Therapy in Metastatic Hepatocellular Carcinoma
Destry Elms1, Ami Badami1, Asha Dhanarajan2
1Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL, USA.
Current Gastroenterology Reports
|April 13, 2022
Summary
New systemic therapies, including atezolizumab and bevacizumab, are now standard for advanced hepatocellular carcinoma (HCC). While improving survival, options remain limited for patients with advanced liver disease (Child-Pugh B).
Area of Science:
- Hepatobiliary Oncology
- Medical Oncology
- Pharmacotherapy
Background:
- Advanced hepatocellular carcinoma (HCC) treatment landscape has evolved with novel therapies.
- Tyrosine kinase inhibitors, immunotherapies, and anti-angiogenic agents are now available.
Purpose of the Study:
- To review the evidence supporting new systemic therapies for advanced HCC.
- To evaluate current treatment standards and future directions.
Main Methods:
- Systematic review of clinical trial data and guidelines.
- Analysis of efficacy and safety profiles of novel agents.
Main Results:
- Atezolizumab plus bevacizumab is a new standard of care, replacing sorafenib in first-line therapy for eligible patients.
- Lenvatinib offers an alternative first-line option for patients ineligible for immunotherapy.
- Several second-line treatment options were also detailed, prolonging overall survival.
Conclusions:
- New systemic therapies have significantly improved survival in advanced HCC.
- Current approvals predominantly favor patients with Child-Pugh A classification, highlighting a need for more options in Child-Pugh B disease.
- Further research is required to optimize treatment sequencing and expand therapeutic options for patients with more advanced liver disease.
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:27Tumor Immunotherapy
691
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
691
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K